Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has turned down Summit Therapeutics' application for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC), saying the drug failed to show a statistically significant overall survival improvement. The phase 3 HARMONi trial did show a meaningful progression-free survival benefit, but that wasn't enough to clear the bar. Patients in this setting still have no FDA-approved regimen with a proven survival advantage.
The FDA has issued a complete response letter (CRL) to Summit Therapeutics, rejecting its biologic license application for ivonescimab — a bispecific antibody targeting PD-1 and VEGF — in combination with platinum-based chemotherapy for patients with EGFR-mutated, locally advanced or metastatic NSCLC who previously received EGFR tyrosine kinase inhibitor (TKI) therapy.
The agency's decision hinged on one key issue: the absence of a statistically significant overall survival (OS) improvement. While the phase 3 HARMONi trial demonstrated a meaningful progression-free survival (PFS) benefit, the OS data fell just short of statistical significance — and the FDA wasn't willing to approve on PFS alone.
Summit remains committed to ivonescimab's development, pointing to five positive phase 3 studies across its pipeline and ongoing trials in colorectal, urothelial, renal cell, breast, and GI cancers.
By the Numbers:
Why it matters: This rejection leaves a significant gap — there are currently no FDA-approved regimens for this patient population with a proven OS benefit, underscoring the continued unmet need in post-EGFR TKI NSCLC treatment.